

BioInvent International AB (publ) appoints Vice President

Lund, Sweden: In connection with the merger between BioInvent International AB (publ) and its subsidiaries BioInvent Production AB and BioInvent Therapeutic AB, the board of directors has today appointed Cristina Glad (50) as Vice President of the company, starting today. Cristina, Doctor of Science, biochemistry and MBA, has worked within the BioInvent group since 1987 inter alia as Director of Manufacturing and Business Development 1990 – 1997 and holds since 1997 the position of President of BioInvent Production AB.

-- END --

For more information please contact

BioInvent International AB

Svein Mathisen
President and CEO
Tel.: +46 46 286 85 67
Mobile: +46 708 97 82 13
E-mail: sm@bioinvent.com

Buchanan Communications

Nicola How
Tel: +44 20 7466 5000

Notes to Editors:

BioInvent International AB, listed on the O-list of the Swedish Exchange, is a biotechnology company devoted to providing state-of-the-art antibody technology to the pharmaceutical and biotech industry. A cornerstone is its proprietary human antibody gene library, n-CoDeR™. This is a collection of more than ten billion functional antibody genes that are ready to be screened against desired antigens. n-CoDeR™ has been used successfully for the isolation of antibody fragments with specificity for a number of antigens, including peptides, proteins and carbohydrates. BioInvent offers biotechnology and pharmaceutical companies access to n-CoDeR™ through collaborative research and development programs.

BioInvent's capabilities in large-scale contract manufacturing of protein-based drugs through a state-of-the-art cGMP-certified facility further underpin its competitiveness in the antibody arena. BioInvent has been supplying monoclonal antibodies, fusion proteins and other recombinant proteins to the world's leading pharmaceutical and biotechnology companies for therapeutic use since 1988. These antibodies and proteins are used in all phases of clinical trials in both the US and across Europe. The cGMP-certified manufacturing facility is designed to meet FDA and EU regulations from early clinical development to commercial scale-up, with multi-kilogram annual capacity.

BioInvent is headquartered in Lund, Sweden, employing a total of 125 people.

For further information, see www.bioinvent.com